Jeff Hargroves is the Founder and former President and CEO of ProPharma Group, a global provider of regulatory, clinical, pharmacovigilance, medical information and compliance consulting services to the pharmaceutical, biotechnology and medical device industries.
Prior to founding ProPharma Group, Mr. Hargroves held positions in operations, quality assurance and engineering within the pharmaceutical manufacturing and consulting sectors. As an industry consultant, he has conducted numerous regulatory audits, developed quality systems and programs, and managed projects involving bulk and finished pharmaceuticals for both human and animal health applications. He also has extensive experience in the design and validation of pharmaceutical facilities, utilities, process equipment and manufacturing processes for sterile and non-sterile products and active pharmaceutical ingredients.
Mr. Hargroves is active in several industry organizations, including ISPE, PDA, DIA, RAPS, FDLI, IVT and BioKansas. He earned Bachelor of Science degrees in Computer Engineering and Electrical Engineering from the University of Missouri.
What is Thomas Jeffrey Hargroves' net worth?
The estimated net worth of Thomas Jeffrey Hargroves is at least $506.35 thousand as of February 13th, 2026. Mr. Hargroves owns 97,468 shares of Cingulate stock worth more than $506,346 as of September 18th. This net worth evaluation does not reflect any other investments that Mr. Hargroves may own. Learn More about Thomas Jeffrey Hargroves' net worth.
How do I contact Thomas Jeffrey Hargroves?
Has Thomas Jeffrey Hargroves been buying or selling shares of Cingulate?
Thomas Jeffrey Hargroves has not been actively trading shares of Cingulate during the last quarter. Most recently, on Friday, February 13th, Thomas Jeffrey Hargroves bought 97,276 shares of Cingulate stock. The stock was acquired at an average cost of $5.04 per share, with a total value of $490,271.04. Following the completion of the transaction, the director now directly owns 97,468 shares of the company's stock, valued at $491,238.72. Learn More on Thomas Jeffrey Hargroves' trading history.
Who are Cingulate's active insiders?
Are insiders buying or selling shares of Cingulate?
In the last year, Cingulate insiders bought shares 5 times. They purchased a total of 130,350 shares worth more than $656,964.00. The most recent insider tranaction occured on February, 13th when Director
Thomas Jeffrey Hargroves bought 97,276 shares worth more than $490,271.04. Insiders at Cingulate own 5.3% of the company.
Learn More about insider trades at Cingulate. Information on this page was last updated on 2/13/2026.
